Post-marketing Safety Literature Analysis and Risk Control Recommendations of Shuxuening Injection

Abstract

Abstract: Shuxuening injection is the ginkgo preparation which is widely used in clinic. By retrospective study on shuxuening injection post-marketing safety status in the literature at home and abroad, it is found that the main adverse reactions of allergic reactions with the characteristics of immediate hypersensitivity, alone or in combination may cause risk. Serious adverse reactions mainly involved anaphylactoid reaction, allergic shock, respiratory system damage with difficult breathing, cardiovascular system damage with chest tightness and palpitation. There are very rare literatures reported bleeding. We put forward risk control measures in accordance with the drug itself characteristics, and suggestions for safe and rational use of the drug.

Key words: Shuxuening injection, literature analysis, risk control, recommendation

CLC Number:

R286
R994.11

YANG Le, WANG Yan-chun ,DU Xiao-xi, REN Jing-tian ,Song Hai-bo, LIU Xi-dan. Post-marketing Safety Literature Analysis and Risk Control Recommendations of Shuxuening Injection [J]. Chinese Journal of Pharmacovigilance, 2013, 10(9): 553-556.

References

[1] 廖媛晖.舒血宁注射液过敏反应2 例[J].保健医学研究与实践,2008,5(4):92.
[2] 王淑霞.舒血宁注射液致过敏性休克1例[J].中国药物警戒,2009,6(3):180.
[3] 韩丽华,王蕾.舒血宁致不良反应3 例[J].现代医药卫生,2008,24(19):2989.
[4] 王建娜,张淑惠.舒血宁注射液不良反应2 例[J].临床医学,2010,5(77):128.
[5] 杨艳春,郑本献.静脉滴注舒血宁致老年糖尿病患者子宫出血一例[J].人民军医,2012,2(55):154.
[6] 李征北.舒血宁注射液治疗400 例不稳定型心绞痛的疗效和不良反应观察[J].中国医药指南,2011,8(9):23.
[7] 孟利娟.舒血宁与阿昔洛韦存在配伍禁忌[J].现代中西医结合杂志,2008,17(23):3615.
[8] 李艳玲,韩玉娥,魏云英.舒血宁与氨茶碱存在配伍反应[J].河北职工医学院学报,2005,21(4):21.
[9] 董秋玉,王希香,刘娜.舒血宁与碳酸氢钠存在配伍禁忌[J].中国临床研究,2011,24(3):248.
[10] 曾岩洁,刘亚东,李雪芹.舒血宁与呋塞米存在配伍禁忌[J].中国实用护理杂志,2008,24(7B):41.
[11] 王希.舒血宁与前列地尔存在配伍禁忌[J].中国误诊学杂志,2011,11(7):1731.
[12] 王艳.脂肪乳与舒血宁和门冬酸钾镁存在配伍禁忌[J].中国实用护理杂志,2010,26(1A):43.
[13] 余喜梅.注射用奥美拉唑与舒血宁注射液存在配伍禁忌[J].中国误诊学杂志,2008,8(29):7244.
[14] 赵丽华,朱建英.舒血宁与阿莫西林钠克拉维酸钾存在配伍禁忌[J]. 新医学学刊,2008,5(9):1536.
[15] 杨莉,刘桂英.舒血宁注射液加重头孢曲松钠致凝血障碍1例[J].中国药物应用与监测,2010,7(3):188-189.
[16] 张蓬华,肖淼生,张静,等. 舒血宁注射液与五种注射液配伍后的稳定性考察[J].中国药师,2009,12(2):259-260.
[17] 杨德平.154 例舒血宁注射液的严重不良反应分析[J].中国药物警戒,2010,10(7):620.
[18] 纪立伟,李晓翠,李可欣.26例舒血宁注射液不良反应报告分析[J].中国药物应用与监测,2011,8(4):228.
[19] 黄蓓.舒血宁不良反应文献分析[J].中国医院用药评价与分析,2009,9（12）：945.
[20] 赵志茹,谢乾松,吴晓凤.银杏制剂的药理作用及临床应用研究进展[J].中医药研究,2001,17(5)：54.
[21] 张东华,董强波,董建敏.银杏叶提取物的化学成分、药理作用和临床应用研究概况[J].现代保健医学创新研究,2007,4(12)：35.
[22] 吕英琦,李彩霞,刁景丽. 舒血宁致17 例不良反应分析[J].疾病监测与控制杂志,2010,4（6）：371.
[23] 姜淼,卞慧敏.银杏内酯对家兔血小板聚集率的影响[J]. 南京中医药大学学报,2008( 24):197-199.
[24] 沈连忠,崔艳英,王淑仙.银杏叶提出物血液流变学研究[J].中国中药杂志,1998,23(10)：622-623.
[25] Rosenblatt M,Mindel J.Spontaneous hyphema associated with ingestion of Ginkgo bilobaextract[J].NEngl JMed,1997,336：1108.
[26] Meisel C,Johne A,Roots I.Fatal intracerebral mass bleeding associatedwithGinkgobilobaandibuprofen[J].Atherosclerosis,2003,167(2)：367.
[27] Eliason BC, Kruger J, Mark D,et al. Dietary supplement users:demographics, product use, and medical system interaction [J].J Am Board Fam Pract,1997,10(4):265-271.
[28] Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.Arch.Intern[J]. Med,1998,158(20):2200-2211.
[29] Dugoua J J, Mills E, Perri D,et al. Safety and efficacy of ginkgo(Ginkgo biloba)during pregnancy and lactation[J]. Can J Clin.Pharmacol,2006,13(3):e277-e284.